TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26797214

Group type: EXPERIMENTAL
Intervention: Efavirenz-based cART
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atazanavir/Ritonavir-based cART
Number of subjects: 30

Group type: COMPARATOR
Intervention: No cART
Number of subjects: 30
Study: 26797234

Group type: EXPERIMENTAL
Intervention: Incident diabetes complications (any one of the seven complications: stroke, heart failure, myocardial infarction, ischemic heart disease, renal failure, blindness, and amputation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amputation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blindness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renal failure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Myocardial infarction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ischemic heart disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elapsed time
Number of subjects: 0
Study: 26797464

Group type: EXPERIMENTAL
Intervention: 2-day interactive educational seminar on evidence-based guidelines about managing RTIs
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (no seminar)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Both intervention modalities (seminar and problem-solving training)
Number of subjects: 203
Study: 26797802

Group type: EXPERIMENTAL
Intervention: Imatinib (300-400 mg daily for ≥ 1 month)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Imatinib therapy
Number of subjects: 27
Study: 26798624

Group type: EXPERIMENTAL
Intervention: Clarithromycin (12 weeks course)
Number of subjects: 32
Study: 26798647

Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual clinical practice (control)
Number of subjects: 0
Study: 26798650

Group type: EXPERIMENTAL
Intervention: DCM-AGT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DCM-NGT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: N-AGT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DCM patients
Number of subjects: 10
Study: 26798977

Group type: EXPERIMENTAL
Intervention: Corticosteroid implant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic therapy
Number of subjects: 0
Study: 26799743

Group type: EXPERIMENTAL
Intervention: L-arginine (3 x 2.5 g/d) and metformin (2 x 250 mg/d) for 16 weeks
Number of subjects: 5
Study: 26800061

Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Number of subjects: 7170
Study: 26800632

Group type: EXPERIMENTAL
Intervention: Psychological attribution and emotional awareness and expression therapy
Number of subjects: 72
Study: 26800789

Group type: EXPERIMENTAL
Intervention: HEART Pathway ADP implementation
Number of subjects: 10000
Study: 26800997

Group type: EXPERIMENTAL
Intervention: 2.5 μg of ramosetron for 4 weeks, continued for another 48 weeks for responders
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 5 μg of ramosetron for 48 weeks for non-responders
Number of subjects: 151
Study: 26801409

Group type: EXPERIMENTAL
Intervention: Lung Cancer Risk Test (LCRT), a 15 gene test measured in normal bronchial epithelial cells (NBEC)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Bronchoscopic brushing for NBEC sample collection
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Establishment of an NBEC and matched peripheral blood bio-specimen repository
Number of subjects: 403
Study: 26801909

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Artemisinin combination therapy (ACT)
Number of subjects: 32
Study: 26801983

Group type: EXPERIMENTAL
Intervention: Space GlucoseControl system (SGC) with enhanced Model Predictive Control (eMPC) algorithm
Number of subjects: 508
Study: 26802021

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 755
Study: 26802181

Group type: EXPERIMENTAL
Intervention: Ultrasound imaging of 32 joints (wrists, metacarpophalangeal joints, proximal interphalangeal joints, metatarsophalangeal joints)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Ultrasound abnormalities (GS ≥2, PD ≥1 or erosion ≥1)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Power Doppler signal
Number of subjects: 136
Study: 26803277

Group type: EXPERIMENTAL
Intervention: Ivacaftor 50 mg (if bodyweight <14 kg) or 75 mg (if bodyweight ≥14 kg) every 12 h for 4 days (part A) and then for 24 weeks (part B)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ivacaftor 50 mg or 75 mg
Number of subjects: 43
Study: 26803420

Group type: EXPERIMENTAL
Intervention: Transfemoral transcatheter aortic valve replacement (TF-TAVR)
Number of subjects: 1063
Study: 26803446

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir (90 mg ledipasvir and 400 mg sofosbuvir orally once per day for 12 weeks)
Number of subjects: 41
Study: 26803597

Group type: EXPERIMENTAL
Intervention: Low PAMP diet for 7 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: High PAMP diet after 4 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fresh onion meal
Number of subjects: 24

Group type: COMPARATOR
Intervention: High PAMP equivalent meal
Number of subjects: 24
Study: 26803754

Group type: EXPERIMENTAL
Intervention: Transient hepatic elastography (THE) using FibroScan® device
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Controlled Attenuation Parameter (CAP) software
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HbA1c and HOMA-IR
Number of subjects: 50
Study: 26804761

Group type: EXPERIMENTAL
Intervention: Raindrop Near Vision Inlay
Number of subjects: 373
Study: 26805452

Group type: EXPERIMENTAL
Intervention: LA expansion index measurement
Number of subjects: 141
Study: 26806010

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (600 mg fixed dose via SC single-use injection device)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (via SC handheld syringe)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous trastuzumab
Number of subjects: 0
Study: 26806047

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 690

Group type: COMPARATOR
Intervention: Continued medical management
Number of subjects: 690
Study: 26806518

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 2563

Group type: EXPERIMENTAL
Intervention: Lithium monotherapy
Number of subjects: 2563
Study: 26806840

Group type: EXPERIMENTAL
Intervention: QRS score ≥ 5
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: QRS score ≥ 6
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: T-wave alternans (TWA) value
Number of subjects: 77
Study: 26808615

Group type: EXPERIMENTAL
Intervention: PRM(fSAD) in participants without airflow obstruction
Number of subjects: 1508

Group type: EXPERIMENTAL
Intervention: PRM(fSAD) in GOLD 1-4 participants
Number of subjects: 1508

Group type: EXPERIMENTAL
Intervention: PRM(emph) in GOLD 1-4 participants
Number of subjects: 1508

Group type: EXPERIMENTAL
Intervention: CT metrics contribution to FEV1 decline in GOLD 1/2
Number of subjects: 1508

Group type: EXPERIMENTAL
Intervention: CT metrics contribution to FEV1 decline in GOLD 3/4
Number of subjects: 1508
Study: 26808671

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg orally
Number of subjects: 24
Study: 26809001

Group type: EXPERIMENTAL
Intervention: Contour and Contour TS blood glucose monitoring systems
Number of subjects: 100
Study: 26809204

Group type: EXPERIMENTAL
Intervention: Illicit drug use (e.g., marijuana, cocaine, heroin)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Prescription drug misuse
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Heavy drinking in the past 3 months
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: High-risk alcohol use
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Pain-related dysfunction
Number of subjects: 589
Study: 26810133

Group type: EXPERIMENTAL
Intervention: ABCC3 allele A at rs4148412
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: ABCC3 allele G at rs729923
Number of subjects: 316
Study: 26810139

Group type: EXPERIMENTAL
Intervention: Automated Telephonic Assessment (ATA) calls
Number of subjects: 125
Study: 26810441

Group type: EXPERIMENTAL
Intervention: Treatment for allergic rhinitis
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Assessment of extranasal symptoms
Number of subjects: 260
Study: 26810581

Group type: EXPERIMENTAL
Intervention: Bi-weekly Pemetrexed (PEM) at 500 mg/m(2) combined with weekly Cisplatin (CDDP) and standard dose External Beam Radiation Therapy (EBRT)
Number of subjects: 10
Study: 26810651

Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ethambutol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Rifampin (two formulations)
Number of subjects: 39

Group type: COMPARATOR
Intervention: HIV status
Number of subjects: 39
Study: 26810758

Group type: EXPERIMENTAL
Intervention: End tidal CO2 (etco2) measurement greater than or equal to 50 mm Hg
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale score at inclusion
Number of subjects: 201
Study: 26811129

Group type: COMPARATOR
Intervention: Isocaloric diet lower in sodium and protein and higher in fruits, vegetables, and water for 4 weeks
Number of subjects: 12
Study: 26811163

Group type: EXPERIMENTAL
Intervention: Patient-reported rehospitalizations
Number of subjects: 10643

Group type: COMPARATOR
Intervention: Medical bills
Number of subjects: 10643
Study: 26812041

Group type: EXPERIMENTAL
Intervention: MAPP (Mood Action Psychology Programme)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Weekly mood monitoring and treatment target data
Number of subjects: 14
Study: 26812512

Group type: EXPERIMENTAL
Intervention: Fish oil (EPA+DHA: 2.4 g/d)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 21
Study: 26812968

Group type: EXPERIMENTAL
Intervention: WHtR (waist-to-height ratio)
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Fat-free mass, heart rate, stature
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: WHtR
Number of subjects: 730
Study: 26813675

Group type: EXPERIMENTAL
Intervention: Ibrutinib treatment (≥5 cycles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibrutinib treatment (≥1 year)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibrutinib exposure
Number of subjects: 0
Study: 26813737

Group type: EXPERIMENTAL
Intervention: MoodHacker intervention (n=150)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: MoodHacker intervention (n=150) with EAP access
Number of subjects: 300

Group type: COMPARATOR
Intervention: Alternative care (n=150)
Number of subjects: 300
Study: 26814219

Group type: EXPERIMENTAL
Intervention: Out-patient pulmonary rehabilitation (PR) program for 8 weeks
Number of subjects: 11
Study: 26814234

Group type: EXPERIMENTAL
Intervention: Cortical venous filling (CVF) assessed with dynamic CT angiography
Number of subjects: 88

Group type: COMPARATOR
Intervention: Model without CVF information
Number of subjects: 88
Study: 26814884

Group type: EXPERIMENTAL
Intervention: Balloon therapy for stress urinary incontinence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Muscle-derived stem cells for stress urinary incontinence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pudendal nerve stimulation for overactive bladder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravesical liposomes for drug delivery in interstitial cystitis/painful bladder syndrome
Number of subjects: 0
Study: 26817140

Group type: EXPERIMENTAL
Intervention: Electronic nose breath-print analysis
Number of subjects: 52
Study: 26817280

Group type: EXPERIMENTAL
Intervention: Urinary HOM and body mass index
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CsA dosage regimen based on urinary HOM
Number of subjects: 54
Study: 26817606

Group type: EXPERIMENTAL
Intervention: Low intensity aerobic exercise training, performed four times per week for 12 weeks.
Number of subjects: 22
Study: 26818566

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir-based antiretroviral therapy with artemether-lumefantrine treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Antiretroviral-naïve group with artemether-lumefantrine treatment
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Lopinavir group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Antiretroviral-naïve group
Number of subjects: 34
Study: 26818847

Group type: EXPERIMENTAL
Intervention: Robot walking sessions for 45 min daily over 20 sessions
Number of subjects: 3
Study: 26819054

Group type: EXPERIMENTAL
Intervention: CD34(+)CD38(-) leukemia cells with high aldehyde dehydrogenase activity
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: CD34(+)CD38(-) leukemia cells with intermediate aldehyde dehydrogenase expression
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: No CD34(+) leukemia cells
Number of subjects: 109
Study: 26819296

Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stromal cell (MSC) infusion, 2 infusions 1 week apart after 8 weeks of MSC culture expansion.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Autologous MSC treatment
Number of subjects: 10
Study: 26819573

Group type: EXPERIMENTAL
Intervention: Intervention to reduce heavy drinking among Hispanics
Number of subjects: 0
Study: 26819724

Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium (2×256 mg, equivalent to 400 mg standard ibuprofen)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Standard ibuprofen (2×200 mg)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Standard ibuprofen
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium vs Standard ibuprofen
Number of subjects: 226
Study: 26819748

Group type: EXPERIMENTAL
Intervention: Combination therapy (TNFi + csDMARD such as methotrexate)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Monotherapy (TNFi only)
Number of subjects: 519
Study: 26819752

Group type: EXPERIMENTAL
Intervention: ADA + MTX (arm AM)
Number of subjects: 31

Group type: COMPARATOR
Intervention: MTX monotherapy (arm M)
Number of subjects: 31
Study: 26820403

Group type: EXPERIMENTAL
Intervention: Three-dimensional high-resolution anorectal manometry (3DHRAM)
Number of subjects: 61
Study: 26820771

Group type: EXPERIMENTAL
Intervention: Intermenstrual bleeding
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Luteal bleeding
Number of subjects: 549
Study: 26821198

Group type: EXPERIMENTAL
Intervention: 4 common depression rating scales (1 self-report, 3 clinician-report)
Number of subjects: 3509

Group type: EXPERIMENTAL
Intervention: Overall depression levels
Number of subjects: 3509

Group type: EXPERIMENTAL
Intervention: Sum-scores of depression
Number of subjects: 3509
Study: 26821583

Group type: EXPERIMENTAL
Intervention: CoCr-EES
Number of subjects: 2010
Study: 26822149

Group type: EXPERIMENTAL
Intervention: Individualized cancer therapy (iCat) recommendations based on tumor profiling
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Matched therapy based on iCat recommendations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tumor profiling for actionable alterations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Identification of alterations with clinical significance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Common actionable alterations leading to iCat recommendations
Number of subjects: 100
Study: 26822279

Group type: EXPERIMENTAL
Intervention: 40 mg low-dose aspirin
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Higher-dose aspirin challenges (up to 325 mg)
Number of subjects: 29
Study: 26822328

Group type: EXPERIMENTAL
Intervention: Automatic personalized feedback via reinforcement learning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26822963

Group type: EXPERIMENTAL
Intervention: Septic shock and cardiogenic shock patients (n=90)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy blood donors (n=5)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Septic patients (n=10)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acute myocardial infarction or patients with prolonged acute arrhythmia (n=10)
Number of subjects: 90
Study: 26823177

Group type: EXPERIMENTAL
Intervention: Pandemrix (adjuvanted A/H1N1 2009 pandemic influenza vaccine)
Number of subjects: 91
Study: 26823478

Group type: EXPERIMENTAL
Intervention: Nusinersen (ISIS-SMNRx or ISIS 396443) administered intrathecally during lumbar punctures.
Number of subjects: 28
Study: 26823498

Group type: EXPERIMENTAL
Intervention: CRT-D (cardiac resynchronization therapy with defibrillator)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator only therapy
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 537
Study: 26823561

Group type: EXPERIMENTAL
Intervention: In-person training (n = 3 expert interpreters)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Electronic training (n = 5 naïve interpreters)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Visual assessment
Number of subjects: 82
Study: 26823971

Group type: EXPERIMENTAL
Intervention: Tac-OD (once-daily tacrolimus)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CYP3A5 *1/*3 (expressers)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined expresser groups (*1/*1 & *1/*3)
Number of subjects: 60
Study: 26824275

Group type: EXPERIMENTAL
Intervention: mTOR inhibitors
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Linkage to Regional Tumor Registry (RTR)
Number of subjects: 120
Study: 26824901

Group type: EXPERIMENTAL
Intervention: Intravesical injection of 100 U onabotulinumtoxinA (Botox)
Number of subjects: 80
Study: 26824940

Group type: EXPERIMENTAL
Intervention: i.v. acyclovir, 5 mg/kg infused over 60 min (using ideal body weight for obese patients)
Number of subjects: 14

Group type: COMPARATOR
Intervention: i.v. acyclovir, 5 mg/kg infused over 60 min (using total body weight for normal-weight patients)
Number of subjects: 14
Study: 26825111

Group type: EXPERIMENTAL
Intervention: 8 weeks of Internet-based CBT with limited telephone and e-mail support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static webpage listing anxiety resources (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-consequence analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data collection at baseline, treatment completion, and at a 3-month follow-up
Number of subjects: 0
Study: 26825137

Group type: EXPERIMENTAL
Intervention: Self-persuasion intervention (varied by cognitive processing level and choice of argument topics)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Optimal self-persuasion intervention identified in Stage 2
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Self-persuasion intervention
Number of subjects: 350
Study: 26825170

Group type: EXPERIMENTAL
Intervention: EGF816
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGF816 + INC280 (cMET inhibitor)
Number of subjects: 0
Study: 26825231

Group type: EXPERIMENTAL
Intervention: Absorb BVS
Number of subjects: 3389
Study: 26825368

Group type: EXPERIMENTAL
Intervention: Lactate Clearance (LC)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Microcirculatory Flow Index (MFI)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Change in microcirculatory blood flow
Number of subjects: 31
Study: 26825712

Group type: EXPERIMENTAL
Intervention: Defibrotide 25 mg/kg per day
Number of subjects: 102

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 102
Study: 26825925

Group type: EXPERIMENTAL
Intervention: nuMoM2b-HHS study visit including psychosocial and medical history questionnaires, clinical measurements, and biological specimens obtained.
Number of subjects: 10038

Group type: EXPERIMENTAL
Intervention: Objective assessments of sleep-disordered breathing during pregnancy in a subcohort.
Number of subjects: 10038
Study: 26826134

Group type: EXPERIMENTAL
Intervention: PVAC GOLD
Number of subjects: 51

Group type: COMPARATOR
Intervention: ERACE
Number of subjects: 51
Study: 26826513

Group type: EXPERIMENTAL
Intervention: Amygdala
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posterior Superior Temporal Sulcus (STS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fusiform Face Area (FFA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anterior Inferior Temporal Cortex (aIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amygdala and STS
Number of subjects: 0

Group type: COMPARATOR
Intervention: FFA and aIT
Number of subjects: 0
Study: 26826517

Group type: EXPERIMENTAL
Intervention: In vivo 3 T myelin-sensitive images (T1w over T2w ratio images)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vivo 7 T myelin-sensitive images (T1w over T2*w ratio images)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ex vivo proton density-weighted images
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed segmentation scheme
Number of subjects: 0
Study: 26827109

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) targeting thalamus, globus pallidus internus, internal capsule, and nucleus accumbens
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Thalamic stimulation
Number of subjects: 156
Study: 26827659

Group type: EXPERIMENTAL
Intervention: Bortezomib-doxorubicin-dexamethasone reinduction
Number of subjects: 110
Study: 26827881

Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 76

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 76
Study: 26828531

Group type: EXPERIMENTAL
Intervention: High sensitivity cardiac troponin I (cTnI) levels in patients with UMI
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels in patients with UMI
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Galectin-3 levels in patients with UMI
Number of subjects: 235
Study: 26829246

Group type: EXPERIMENTAL
Intervention: Tourniquet use during TKA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 26829377

Group type: EXPERIMENTAL
Intervention: GADD34 gene expression in peripheral blood mononuclear cells (PBMC) of RA patients
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: GADD34 gene expression in PBMC of RA patients
Number of subjects: 75